Robert Croop
Biohaven Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Migraine and Headache Studies, Olfactory and Sensory Function Studies, Trigeminal Neuralgia and Treatments, Botulinum Toxin and Related Neurological Disorders, Psychosomatic Disorders and Their Treatments
Most-Cited Works
- → Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial(2019)385 cited
- → Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine(2019)385 cited
- → Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial(2020)339 cited
- → The Safety Profile of Naltrexone in the Treatment of Alcoholism(1997)214 cited
- → Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial(2023)139 cited
- → Lack of Efficacy of Naltrexone in the Prevention of Alcohol Relapse: Results From a German Multicenter Study(2002)129 cited
- → Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?(2009)114 cited
- → Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine(2020)98 cited
- → Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial(2022)96 cited
- → Naltrexone in the Treatment of Alcohol Dependence: A Combined Analysis of Two Trials(1995)83 cited